I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Earnings Guidance for the Fiscal Year Ending March 2018; Declares Dividend for the Second Quarter of Fiscal 2018, Payable on December 15, 2017
November 09, 2017
Share
I'rom Group Co., Ltd. reported consolidated earnings results for the six months ended September 30, 2017. For the period, net sales were JPY 3,924 million against JPY 1,865 million a year ago. Operating income was JPY 510 million against operating loss of JPY 192 million a year ago. Ordinary income was JPY 558 million against ordinary loss of JPY 214 million a year ago. Net income attributable to owners of parent was JPY 1,240 million against net loss attributable to owners of parent of JPY 216 million a year ago. Diluted net income per share was JPY 107.44.
For the fiscal year ending March 2018, on consolidated basis, the company expects net sales of JPY 9,500 million, operating income of JPY 800 million, ordinary income of JPY 800 million and net income attributable to owners of parent of JPY 1,300 million or JPY 113.92 per share.
The company declared dividend of JPY 10.00 per share for the second quarter of fiscal 2018 against JPY 0.00 a year ago. The expected starting date of dividend payment is December 15, 2017.
I'rom Group Co.,Ltd. is engaged in medical fields such as regenerative medicine and gene discovery. The Company operates through four business segments. The SMO segment provides support services for contracting or substituting a part of the work related to conducting clinical trials from the conducting medical institution. The CRO segment provides all or part of clinical trial operations from pharmaceutical companies and others. The Advanced Medicinal Treatment segment is engaged in the development of gene therapy products, the development, manufacture and sale of products in the field of regenerative medicine based on iPS cells related technologies, as well as the provision of contract manufacture services. The Medical Support segment provides general and comprehensive support for medical business management, such as setting up and renting clinic malls, selling products and related services. The Company also provides business utilizing IT infrastructure.
I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Earnings Guidance for the Fiscal Year Ending March 2018; Declares Dividend for the Second Quarter of Fiscal 2018, Payable on December 15, 2017